Currently, TPO-RAs have been FDA-approved for immune thrombocytopenia in cases of insufficient response to pretreatment, periprocedural thrombocytopenia in patients with chronic liver disease, aplastic anemia, and thrombocytopenia associated with antiviral treatment of hepatitis C [4, 5]. The gene discussed is TPO; the disease is Thrombocytopenia.